IGF1 and acromegaly: In this context, the aim of the present cross-sectional, multicentre study was to determine the effectiveness, as measured by IGF-1 levels, of lanreotide autogel 120 mg administered at dosing intervals >4 weeks for more than 6 months in patients with acromegaly treated in routine clinical practice.